| Drugs by Condition |  |
Osteoarthritis
Definition:
Osteoarthritis is a chronic disease causing deterioration of the joint cartilage (the softer parts of bones, which cushion their connections to each other) and the formation of new bone (bone spurs) at the margins of the joints.
Drugs (by generic name) associated with Osteoarthritis
The following drugs and medications are in some way related to, or used in the treatment of Osteoarthritis.
This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Osteoarthritis Related Drugs in the Pipeline
Pennsaid (diclofenac sodium)
- June 19, 2007
Nuvo Provides Update on Discussions with the FDA Related to Pennsaid Approval - June 6, 2007
Nuvo Continues Discussions with the FDA Related to Pennsaid - March 7, 2007
Nuvo announces further update on discussions with the FDA related to review of Pennsaid - February 9, 2007
Nuvo Announces Update on Discussions With FDA Related to Approval of Pennsaid - December 29, 2006
Nuvo Receives Approvable Letter From U.S. FDA for Pennsaid - July 13, 2006
Nuvo’s Pennsaid NDA Resubmission Accepted for Review by U.S. FDA
Arcoxia (etoricoxib)
- April 27, 2007
Merck Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib) - April 13, 2007
Public Citizen: FDA Should Not Approve "Offspring of Vioxx" Painkiller - April 12, 2007
FDA Advisory Committee Recommends Against Approval for Merck's NDA for Arcoxia (etoricoxib) - April 11, 2007
Statement by Merck & Co., Inc. Regarding FDA Arthritis Drugs Advisory Committee Meeting on Arcoxia (etoricoxib) - April 9, 2007
Arthritis Foundation Chief Public Health Officer Testifies at FDA Hearing on Arcoxia - November 10, 2006
Merck Responds to FDA-Issued Approvable Letters for Arcoxia (etoricoxib) - June 17, 2005
Merck Provides Status Update on Ongoing Arcoxia Trials - October 29, 2004
Merck Receives ’Approvable’ Letter for Arcoxia
Prexige (lumiracoxib)
Learn more about Osteoarthritis
Medical encyclopedia results for:
